Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 297Lung Neoplasms 195Colorectal Neoplasms 54Small Cell Lung Carcinoma 52Neoplasms 39Ovarian Neoplasms 38Melanoma 37Pancreatic Neoplasms 33Breast Neoplasms 31Neoplasm Metastasis 27Stomach Neoplasms 26Squamous Cell Carcinoma of Head and Neck 24Carcinoma, Renal Cell 22Urinary Bladder Neoplasms 20Prostatic Neoplasms 20Esophageal Neoplasms 20Endometrial Neoplasms 20Head and Neck Neoplasms 19Triple Negative Breast Neoplasms 18Colonic Neoplasms 18Uterine Cervical Neoplasms 16Carcinoma, Hepatocellular 16Mesothelioma 15Lung Diseases 13Sarcoma 12Parkinson Disease 4, Autosomal Dominant Lewy Body 12Mesothelioma, Malignant 12Adenocarcinoma of Lung 11Cholangiocarcinoma 10Rectal Neoplasms 9

Interventions

cemiplimab 1Pemetrexed 1Paclitaxel 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Resectable Non-small Cell Lung Cancer × Thoracic × 30 days × Clear all
NCT06161441 2026-05-28

A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

Regeneron Pharmaceuticals

Phase 2 Active not recruiting
195 enrolled
Thoracic

Resectable Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡